eli lilly glp-1 drugs US approves new oral weight-loss pill developed by | US news eli lilly oral glp-1 Eli
Description
With obesity now recognized as a chronic disease requiring long-term management, these innovative drugs could transform weight loss from a struggle to a science, giving patients powerful, sustainable solutions
Conflict of interest The author has provided advisory services to AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, and Novo Nordisk, and has received lecture honoraria from Bristol Myers Squibb, Novartis and the above-mentioned companies
10.1016/s2213-8587(21)00179-0
These data are consistent with the demonstration that i.v
